Answers are grounded in this paper and cite their sources.
Routine linear accelerator quality assurance (QA) primarily characterizes beam constancy under simple irradiation conditions, whereas dynamic multileaf collimator (DMLC) performance is generally assessed with dedicated periodic tests. This study evaluated the long-term clinical implementation and additional information provided by a daily 6 MV flattening-filter-free (6FFF) DMLC QA field used together with an energy-matched 6FFF open-field measurement. Routine morning QA data acquired from May 2024 to August 2026 on two Elekta Versa HD linear accelerators were retrospectively evaluated using two independent electronic portal imaging device (EPID)-based dosimetry workflows: EPIbeam (DOSIsoft) for pretreatment verification and iViewDose for in vivo dose reconstruction. Each workflow was analyzed separately using its institutional Pass, Alert, and Action levels. The analysis included 548 EPIbeam QA sessions and 490 iViewDose QA sessions containing both 6FFF open-field and DMLC measurements. When the open-field result was Pass, the DMLC result reached Alert or Action in 35/531 EPIbeam sessions (6.6%; 95% CI, 4.8-9.0%) and 85/489 iViewDose sessions (17.4%; 95% CI, 14.3–21.0%); the reverse discordance occurred only once in each workflow (both p < 0.001). Mean gamma and the upper 1% gamma value provided additional longitudinal information beyond the gamma passing rate (GPR). In routine clinical use, the complete morning QA workflow was generally completed in < 5 min with EPIbeam and < 10 min with iViewDose. Daily DMLC monitoring therefore provided a practical additional assessment of dynamic delivery constancy within routine EPID-based linac QA.
No takes yet. Share an insight, caveat, or question.
Biltekin¹ et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: